The treatment, an investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, met its primary endpoints in both trials, delivering substantial weight loss across high-risk populations including adults with type 2 diabetes and those with severe obesity and established cardiovascular disease
Fatigue was slightly more likely with semaglutide, while injection site reactions were reported more with tirzepatide
We are committed to your success and will be by your side as you seek to maximize your health
By modulating dopamine levels, these medications could potentially impact the reinforcing effects of addictive behaviors
Ready to give your hardworking liver the support it deserves
It is the cleavage product of GLP-1 (1-36) amide peptide